CSPC Pharmaceutical Group Ltd 2016 AR2
The report highlights CSPC Pharmaceutical Group Limited's financial and sustainability performance for the fiscal year 2016. The company recorded a 8.6% growth in sales to HK$12,369 million, driven by its finished drug business, particularly innovative drugs like NBP and Jinyouli. CSPC published its first Environmental, Social, and Governance (ESG) report, detailing its efforts in environmental protection, including ISO14001 certification for major subsidiaries and advanced wastewater treatment. The group also focused on employee development, occupational health and safety, and community investment through the Hebei CSPC Pu'en Charity Foundation.
Company: CSPC Pharmaceutical Group Ltd
Sector: Health Care
Country: China
Year: 2016
Type: AR2
Pages: 151
Back to company
CSPC Pharmaceutical Group Ltd
Annual Report
The report highlights CSPC Pharmaceutical Group Limited's financial and sustainability performance for the fiscal year 2016. The company recorded a 8.6% growth in sales to HK$12,369 million, driven by its finished drug business, particularly innovative drugs like NBP and Jinyouli. CSPC published its first Environmental, Social, and Governance (ESG) report, detailing its efforts in environmental protection, including ISO14001 certification for major subsidiaries and advanced wastewater treatment. The group also focused on employee development, occupational health and safety, and community investment through the Hebei CSPC Pu'en Charity Foundation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Workplace Fatalities
Employees